| Compound | MOTS-c |
|---|---|
| Category | Mitochondrial-derived peptide |
| Class | Metabolic and Mitochondrial Compounds |
| Evidence tier | Preclinical |
| WADA status | Not individually listed; verify current status if subject to testing |
| Sold on this site | No — this is a reference database |
Overview
This entry covers MOTS-c, a mitochondrial-derived peptide, graded "Preclinical" in this catalog's evidence system. The evidence base for this compound is dominated by animal and cell-culture studies. Mechanism may be plausible; human benefit and safety are unestablished.
A peptide encoded in the mitochondrial genome, studied as an exercise-mimetic and metabolic regulator in laboratory models.
Mechanism of Action
MOTS-c is reported to activate AMPK and improve metabolic parameters in mice, with circulating levels reported to respond to exercise.
Research and Evidence
Evidence is predominantly animal and cell-culture; small human observational studies exist. No interventional trials of significance have been completed.
Safety and Side Effects
No human safety data for administration.
Frequently Asked Questions
What is the evidence tier of MOTS-c?
MOTS-c is graded "Preclinical" on this site. The evidence base for this compound is dominated by animal and cell-culture studies. Mechanism may be plausible; human benefit and safety are unestablished.
Is MOTS-c an approved medicine?
No. Preclinical means the compound has not reached universal regulatory approval; the tier description above explains exactly what level of evidence exists.
Where can I read the primary studies for MOTS-c?
The references section at the end of this entry links the key primary sources — regulator labels, trial registrations, and peer-reviewed papers. Our "How to Read a Peptide Study" guide explains how to evaluate them.
References
- ClinicalTrials.gov — search for MOTS-c studies. [source]
Evidence tier: Preclinical · Last reviewed: 2026-09-05 · Sources cited below.